FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. | 20549 |
|-------------|------|-------|

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL | | | | | | | | | | |
|--------------------------|-----|--|--|--|--|--|--|--|--|--|
| OMB Number: 3235-028 | | | | | | | | | | |
| Estimated average burden | | | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* Cohen Chad M | | | | | | 2. Issuer Name and Ticker or Trading Symbol Adaptive Biotechnologies Corp [ADPT] | | | | | | | | heck all ap Dire | son(s) to Iss 10% O Other (| wner | | | |
|--|---|--|---|--------|---------------------------------------|---|-------|---|--|--|--------------------|---|---------------------------------------|---|-----------------------------------|---|--|---------------------------------------|--|
| | APTIVE BI | irst) OTECHNOLOG | (Middle) GIES CO | RP. | | 3. Date of Earliest Transaction (Month/Day/Year) 05/08/2020 | | | | | | | | X belo | w) `` | r (give title) Chief Financial | | specify | |
| (Street) SEATTL | E W | | 98102 | | 4.1 | 4. If Amendment, Date of Original Filed (Month/Day/Yea | | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | |
| (City) | (5 | tate) | (Zip) | | | | | | | | | | | | | | | | |
| | | Tab | le I - No | n-Deri | vativ | e Sec | curit | ies Ac | quired | , Dis | sposed o | f, or Be | neficia | lly Own | ed | | | | |
| 1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day | | | | | | Execution Date, | | Transaction Disposed Of (I Code (Instr. | | es Acquired (A) or Of (D) (Instr. 3, 4 and 5) | | 5) Secu Bene | ficially ed Following | Forn (D) c | | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | | |
| | | | | | | | | | Code | v | Amount | (A) or (D) | Price | Tran | ransaction(s) nstr. 3 and 4) | | | (111511.4) | |
| Common Stock 05/08/2 | | | | 3/2020 | | | | M ⁽¹⁾ | | 20,000 | A | \$6.3 | 2 | 21,000 | | D | | | |
| Common Stock 05/08/20 | | | | | /2020 | 2020 | | | S ⁽¹⁾ | | 20,000 | D | \$35.9 | 2(2) | 1,000 | 000 | | | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | | 4. Transactio Code (Insti 8) | | on of | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | e derivativ | e s ally g | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) | |
| | | | | | Code | v | (A) | (D) | Date Exercisa | ıble | Expiration Date | Title | Amoun or Number of Shares | | | | | | |
| Stock Option (Right To Buy) | \$6.32 | 05/08/2020 | | | М | | | 20,000 | (3) | | 08/25/2025 | Common Stock | 20,000 | \$0.00 | 720,0 | 00 | D | | |

Explanation of Responses:

- 1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019.
- 2. The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from \$35.51 to 36.26, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- 3. The option is fully vested and exercisable.

Remarks:

/s/ Chad Cohen by Eric Billings, Attorney-in-Fact

05/08/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.